Tell Congress: Stop Big Pharma's Control of the FDA

The Trump administration promised to end the FDA's "cozy" relationship with pharmaceutical companies. FDA Commissioner Martin Makary pledged to reform the agency.

Instead, they installed a pharmaceutical industry executive in a key FDA position and increased industry payments to the agency. New investigations reveal expanded industry ties to drug-approval advisory committees and multiple medications approved this year based on questionable scientific evidence.

The FDA increasingly approves drugs based on insufficient evidence while maintaining deep financial relationships with the companies it regulates, putting pharmaceutical profits ahead of patient safety.

Every day this conflict of interest continues, patients risk exposure to inadequately tested drugs while pharmaceutical companies profit from a rigged approval system. Congress must act now to protect public health and restore integrity to our nation's drug regulator.

We demand Congressional action and real reform—not empty promises followed by more industry control.